Oncology Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 By Ecosystem, By Application and By Region

Report
111 Pages
November 2022
Region: Global
TechSci Research
ID: 5689416

The global oncology precision medicine market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. Precision medicine represent the medical approach for the prevention of disease and diagnosis which is based on genetic, environmental, and behavioural variability. It helps in illnesses susceptibility prediction, diseases diagnosis, and progression, as well as medicine prescription. It assists in taking healthcare related decisions, improving quality care, and declining inefficiencies due to the trial-and-error is also augmenting the market growth. Precision medicine is widely utilized to diagnose the chromosomal abnormalities in the foetus and cancer and works for therapy for chronic diseases. The escalating demand of oncology precision medicine methods owing to the growing prevalence of cancer and the expanding number of treatment candidates in clinical trials are fueling the growth of the market.

Increasing Risk of Chronic Diseases in Geriatric Population Drives the Market Growth

Most cancer diagnoses occur in adults over the age of 65 years which demands the accurate treatment plan for this age group. Several oncologists use recommended and available geriatric assessments to help in evaluating older patients and guide their cancer treatment planning. The concept of precision medicine extends beyond tumour-specific markers to incorporate host factors that are assessed as part of a routine geriatric assessment. Oncologists are always careful to stage the cancer in creating cancer treatment plans by giving the importance of staging the aging to ensure that cancer treatments are personalized to as per the patient condition. Assessing the health status of older adults is as important and essential to optimizing treatment as assessing tumour biology and should be included alongside other precision medicine initiatives.

Rise in Use of Targeted Gene Therapy is Expected to Propel the Market Growth

Gene therapy considered as one of the most lucrative markets for precision medicine organizations. Genome sequencing is an unavoidable stage of gene therapy, the extensive investments that are being made in this field drives the growth of the precision medicine market. The increase in number of cancers is escalating the demand for gene therapy as an effective personalized treatment choice across the globe. The significant growth in the number of patients necessitates gene therapy as a potential treatment approach addressing the increasing global burden of the disease. With this, the expanding adoption of emerging genomic technologies, including NGS and high-density microarray, along with the several government initiatives is propelling the market growth.

Market Segmentation

The global oncology precision medicine market is segmented into ecosystem, application, and regional distribution. Based on the ecosystem, the market is divided into precision diagnostics, precision therapeutics, applied sciences, digital health, and information technology. Based on the precision diagnostics, the market is bifurcated into molecular diagnostics and medical imaging. Based on the precision therapeutics, the market is divided into clinical trials, cell therapy, drug discovery & research, gene therapy. Based on the applied sciences, the market is divided into genomics, pharmacogenomics, others. Based on the digital health, and information technology, the market is divided into clinical decision support systems (CDSS), big data analytics, genomics informatics, in-silico informatics, others. Based on application, the market is segmented into insect scouting, crop disease scouting, weed scouting, others. Based on application, the market is bifurcated into solid tumor and hematological malignancies. Based on solid tumor, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, others. Based on hematological malignancies, the market is divided into hodgkin lymphoma, non-hodgkin lymphoma, leukemia, others. The market analysis also studies the regional segmentation, divided among North American region, Asia-Pacific region, European region, South American region, and Middle East & African region.

Market Players

Novartis AG, F. Hoffmann-La Roche AG, Merck & Co., Inc., Danaher Corporation, Abbott Laboratories, Inc., Quest Diagnostics Inc, Eurofins Genomics LLC, Laboratory Corporation of America Holdings, Thermos Fischer Scientific, Inc., bioMérieux SA are the leading market players contributing the growth of the global oncology precision medicine market.

Report Scope:

In this report, global oncology precision medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Oncology Precision Medicine Market, By Ecosystem:

Precision Diagnostics
Precision Therapeutics
Applied Sciences
Digital Health
Information Technology

Oncology Precision Medicine Market, By Precision Diagnostics:

Molecular Diagnostics
Medical Imaging

Oncology Precision Medicine Market, By Precision Therapeutics:

Clinical Trials
Cell Therapy
Drug Discovery & Research
Gene Therapy

Oncology Precision Medicine Market, By Applied Sciences:

Genomics
Pharmacogenomics
Others

Oncology Precision Medicine Digital Health, and Information Technology:

Clinical Decision Support Systems (CDSS)
Big Data Analytics
Genomics Informatics
In-Silico Informatics
Others

Oncology Precision Medicine Market, By Application:

Solid Tumor
Hematological Malignancies

Oncology Precision Medicine Market, By Solid Tumor:

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Others

Oncology Precision Medicine Market, By Hematological Malignancies:

Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Leukemia
Others

Oncology Precision Medicine Market, By Region:

North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Singapore
Malaysia
Europe
Germany
United Kingdom
France
Italy
Spain
Poland
Denmark
South America
Brazil
Argentina
Colombia
Peru
Chile
Middle East & Africa
Saudi Arabia
South Africa
UAE
Iraq
Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global oncology precision medicine market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.

This product will be delivered within 1-3 business days.

1. Product Overview2. Research Methodology3. Executive Summary4. Impact of COVID-19 on Global Oncology Precision Medicine Market

5. Voice of Customer

5.1. Oncology Precision Medicine Awareness
5.2. Cancer Prevalence, By Gender
5.3. Cancer Prevalence, By Age Group
5.4. Cancer Prevalence, Region
5.5. Benefits of Using Precision Medicine in Oncology

6. Clinical Trial Analysis7. Patent Analysis

8. Global Oncology Precision Medicine Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
8.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
8.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
8.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
8.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
8.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
8.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
8.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
8.2.3. By Region
8.2.4. By Company (2021)
8.3. Product Market Map

9. North America Oncology Precision Medicine Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
9.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
9.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
9.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
9.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
9.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
9.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
9.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
9.2.3. By Country
9.3. North America: Country Analysis
9.3.1. United States Oncology Precision Medicine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Ecosystem
9.3.1.2.2. By Application
9.3.2. Mexico Oncology Precision Medicine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Ecosystem
9.3.2.2.2. By Application
9.3.3. Canada Oncology Precision Medicine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Ecosystem
9.3.3.2.2. By Application

10. Europe Oncology Precision Medicine Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
10.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
10.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
10.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
10.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
10.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
10.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
10.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
10.2.3. By Country
10.3. Europe: Country Analysis
10.3.1. France Oncology Precision Medicine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Ecosystem
10.3.1.2.2. By Application
10.3.2. Germany Oncology Precision Medicine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Ecosystem
10.3.2.2.2. By Application
10.3.3. United Kingdom Oncology Precision Medicine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Ecosystem
10.3.3.2.2. By Application
10.3.4. Italy Oncology Precision Medicine Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Ecosystem
10.3.4.2.2. By Application
10.3.5. Spain Oncology Precision Medicine Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Ecosystem
10.3.5.2.2. By Application

11. Asia-Pacific Oncology Precision Medicine Market Outlook

11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
11.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
11.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
11.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
11.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
11.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
11.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
11.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
11.2.3. By Country
11.3. Asia-Pacific: Country Analysis
11.3.1. China Oncology Precision Medicine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Ecosystem
11.3.1.2.2. By Application
11.3.2. India Oncology Precision Medicine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Ecosystem
11.3.2.2.2. By Application
11.3.3. South Korea Oncology Precision Medicine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Ecosystem
11.3.3.2.2. By Application
11.3.4. Japan Oncology Precision Medicine Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Ecosystem
11.3.4.2.2. By Application
11.3.5. Australia Oncology Precision Medicine Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Ecosystem
11.3.5.2.2. By Application

12. South America Oncology Precision Medicine Market Outlook

12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
12.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
12.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
12.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
12.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
12.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
12.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
12.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
12.2.3. By Country
12.3. South America: Country Analysis
12.3.1. Brazil Oncology Precision Medicine Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Ecosystem
12.3.1.2.2. By Application
12.3.2. Argentina Oncology Precision Medicine Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Ecosystem
12.3.2.2.2. By Application
12.3.3. Colombia Oncology Precision Medicine Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Ecosystem
12.3.3.2.2. By Application

13. Middle East and Africa Oncology Precision Medicine Market Outlook

13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
13.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
13.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
13.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
13.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
13.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
13.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
13.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
13.2.3. By Country
13.3. MEA: Country Analysis
13.3.1. South Africa Oncology Precision Medicine Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1. By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1. By Ecosystem
13.3.1.2.2. By Application
13.3.2. Saudi Arabia Oncology Precision Medicine Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1. By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1. By Ecosystem
13.3.2.2.2. By Application
13.3.3. UAE Oncology Precision Medicine Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1. By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1. By Ecosystem
13.3.3.2.2. By Application

14. Market Dynamics

14.1. Drivers
14.2. Challenges

15. Market Trends & Developments16. SWOT Analysis: Global Oncology Precision Medicine Market

17. Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)

17.1. Novartis AG
17.2. F. Hoffmann-La Roche AG
17.3. Merck & Co., Inc.
17.4. Danaher Corporation
17.5. Abbott Laboratories, Inc.
17.6. Quest Diagnostics Inc
17.7. Eurofins Genomics LLC
17.8. Laboratory Corporation of America Holdings
17.9. Thermos Fischer Scientific, Inc.
17.10. bioMérieux SA

18. Strategic Recommendations

Companies Mentioned

Novartis AG
F. Hoffmann-La Roche AG
Merck & Co., Inc.
Danaher Corporation
Abbott Laboratories, Inc.
Quest Diagnostics Inc
Eurofins Genomics LLC
Laboratory Corporation of America Holdings
Thermos Fischer Scientific, Inc.
bioMérieux SA

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4663EUR$4,900USD£3,915GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5615EUR$5,900USD£4,713GBP